|
|
|
| Predictive value of multiparametric MRI for prostate cancer pathology and tumor staging |
| YAO Shangpeng, ZOU Wanji, WANG Shuai |
| Imaging Department of Jingxian Hospital, Jingxian 242500 China |
|
|
|
|
Abstract Objective To evaluate the value of multiparametric MRI for prediction of prostate cancer pathology and tumor staging.Methods A total of 80 patients with prostate cancer admitted during the period from 2016 to 2021 were enrolled as the study subjects, and all patients underwent multiparametric MRI. The pathological examination of radical prostatectomy specimens was used as a gold standard to evaluate the predictive value of multiparametric MRI for significant prostate cancaer, extracapsular extension, index lesion location and lymph node metastasis.Results Multiparametric MRI showed a sensitive of 96%, specificity of 60%, positive predictive value of 97.3% and negative predictive value of 50% for prediction of significant prostate cancer, and the concordance between multiparametric MRI and pathology of radical prostatectomy specimens was 75% for prediction of index lesions. In addition, multiparametric MRI showed a 40% sensitivity, 91.4% specificity, 85.7% positive predictive value and 54.2% negative predictive value for identification of extracapsular extension and a 16.7% accuracy for detection of lymph node metastasis.Conclusion Multiparametric MRI is highly sensitive for predicting significant prostate cancer with a high positive predictive value and is highly accurate for identification of index lesions of prostate cancer, which is of great value to propose prostate cancer treatment schemes and evaluate the clinical prognosis among prostate cancer patients.
|
|
Received: 16 May 2021
|
|
|
|
|
|
[1] Attard G, Parker C, Eeles RA, et al. Prostate cancer[J]. Lancet, 2016, 387(10013): 70-82. DOI: 10.1016/S0140-6736(14)61947-4
[2] Zhai Z, Zheng Y, Li N, et al. Incidence and disease burden of prostate cancer from 1990 to 2017: Results from the Global Burden of Disease Study 2017[J]. Cancer, 2020, 126(9): 1969-1978. DOI: 10.1002/cncr.32733
[3] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660
[4] Launer BM, Lloyd GL. Sociodemographic index and global trends in prostate cancer: 1990-2017[J]. Prostate, 2021, 81(12): 825-831. DOI: 10.1002/pros.24178
[5] Liu X, Yu C, Bi Y, et al. Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China[J]. Public Health, 2019, 172: 70-80. DOI: 10.1016/j.puhe.2019.04.016
[6] Reese AC. Prostate Cancer (Second Edition): Science and Clinical Practice[J]. Pittsburgh: Academic Press, 2016: 353-360. DOI: 10.1016/B978-0-12-800077-9.00039-6.
[7] Cheng L, Montironi R, Bostwick DG, et al. Staging of prostate cancer[J]. Histopathology, 2012, 60(1): 87-117. DOI: 10.1111/j.1365-2559.2011.04025.x
[8] Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS prostate imaging - reporting and data system: 2015, version 2[J]. Eur Urol, 2016, 69(1): 16-40. DOI: 10.1016/j.eururo.2015.08.052
[9] Egevad L, Delahunt B, Evans AJ, et al. International society of urological pathology (ISUP) grading of prostate cancer[J]. Am J Surg Pathol, 2016, 40(6): 858-861. DOI: 10.1097/pas.0000000000000642
[10] Matoso A, Epstein JI. Defining clinically significant prostate cancer on the basis of pathological findings[J]. Histopathology, 2019, 74(1): 135-145. DOI: 10.1111/his.13712
[11] 邵志红, 王伟, 刘卫英, 等. 多参数MRI评估前列腺癌主要病灶体积的价值[J]. 同济大学学报,2021,42(2):214-219, 225. DOI: 10.12289/j.issn.1008-0392.20362
Shao ZH, Wang W, Liu WY, et al. Value of multiparametric MRI sequences in evaluating the index lesion volume of prostate cancer[J]. J Tongji Univ Med Sci, 2021, 42(2): 214-219, 225. DOI: 10.12289/j.issn.1008-0392.20362
[12] 邵志红, 王伟, 刘卫英, 等. 双参数与多参数MRI对不同PSA水平前列腺癌诊断的对比研究[J]. 同济大学学报,2020,41(4):437-442. DOI: 10.16118/j.1008-0392.2020.04.006
Shao ZH, Wang W, Liu WY, et al. Biparametric and multiparametric MRI for diagnosis of prostate cancer in patients with different PSA levels[J]. J Tongji Univ Med Sci, 2020, 41(4): 437-442. DOI: 10.16118/j.1008-0392.2020.04.006
[13] 姬广海, 郑义, 孛茹婷, 等. 多参数MRI对中央腺体前列腺癌的诊断价值[J]. 中国医学影像学杂志,2016,24(8):591-595. DOI: 10.3969/j.issn.1005-5185.2016.08.010
Ji GH, Zheng Y, Bo RT, et al. Multiparametric MRI in the diagnosis of prostatic central gland cancer[J]. Chin J Med Imaging, 2016, 24(8): 591-595. DOI: 10.3969/j.issn.1005-5185.2016.08.010
[14] Xu LL, Zhang G, Shi B, et al. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer[J]. Cancer Imaging, 2019, 19(1): 90. DOI: 10.1186/s40644-019-0274-9
[15] Kam J, Yuminaga Y, Krelle M, et al. Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study[J]. BJU Int, 2019, 124(2): 297-301. DOI: 10.1111/bju.14696
[16] Goldman H, Singh N, Harding C, et al. Accuracy of multiparametric magnetic resonance imaging to detect significant prostate cancer and index lesion location[J]. ANZ J Surg, 2019, 89(1/2): 106-110. DOI: 10.1111/ans.14754
|
|
|
|
